Other Clinical Trial - High-Dose Isoniazid Adjuvant Therapy for Multidrug

Status Completed

Clinical Trial Summary

The need for a standardized treatment protocol for multidrug resistant tuberculosis (MDR-TB) in resource-limited countries is being increasingly recognized. This single center, double blind, randomized controlled trial was designed to compare the time required for sputum culture conversion and extent of radiological improvement in cases of MDR pulmonary tuberculosis when isoniazid was included (both at a regular dose and at a high dose) as an adjuvant to the standardized second line of treatment. The study was designed to test the hypothesis that inclusion of high-dose isoniazid will enhance the effectiveness of the second line of treatment in cases of MDR-TB without significantly increasing the toxicity.

Clinical Trial Description

Tuberculosis was declared a global emergency by the World Health Organization (WHO) in 1993. The global problem of tuberculosis is further complicated by a substantial increase in drug resistant tuberculosis. Available data suggest that drug resistant TB especially multi drug resistant may represent a public health threat in areas with a high prevalence of tuberculosis, suboptimal TB control programmes and/ or HIV. The cure rate of these cases has been reported to be lower than for non-drug resistant TB with a failure rate of 44%. New therapies for MDR-TB have not been introduced since the fluoroquinolones in the 1970s. Strains of Mycobacterium Tuberculosis (M. tub.) in H resistant cases often contain mixture of susceptible & resistant organisms. Use of high dose H (16- 20 mg/kg) can eliminate susceptible & those with low level resistance4. This Study was done to evaluate the role of isoniazid (INH) at high & normal dosages as an adjuvant therapy in treatment of patients with persistent culture positive pulmonary tuberculosis despite 6 months of continuous first line antitubercular treatment and on culture at least resistant to isoniazid and rifampicin. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Tuberculosis
Tuberculosis, Multidrug-Resistant

Clinical Trial Details

NCT number	NCT00513396
Study type	Interventional
Source	GSVM Medical College
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	January 2004
Completion date	December 2006

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05871489` - Strengthening Evidence on Optimal Multidrug-resistant Tuberculosis Treatment Regimens
Active, not recruiting	`NCT02715271` - Study of TB Lesions Obtained in Therapeutical Surgery
Active, not recruiting	`NCT04179500` - A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis Volunteers	Phase 2
Completed	`NCT03086486` - Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis	Phase 3
Completed	`NCT01201941` - Operational Assessment of Laboratory Information System for MDR-TB in Lima, Peru	N/A
Completed	`NCT03303963` - DIAgnostics for Multidrug Resistant Tuberculosis in Africa
Completed	`NCT02413931` - Nosocomial Transmission of MDR-TB in Bucharest, Romania
Recruiting	`NCT05306223` - A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China	Phase 4
Completed	`NCT02573350` - A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683	Phase 2
Completed	`NCT02597621` - Biomarkers for Therapy Response in Drug-resistant Tuberculosis
Recruiting	`NCT05555303` - Preventing Acquired Resistance: Strengthen TB Treatment by Adding Amikacin in the First Treatment Week of Multidrug-resistant Tuberculosis	Phase 2
Recruiting	`NCT03828201` - Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB	Phase 2
Recruiting	`NCT01212003` - Training Protocol on the Natural History of Tuberculosis
Terminated	`NCT03237182` - The Individualized M(X) Drug-resistant TB Treatment Strategy Study	Phase 4
Completed	`NCT03338621` - Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients	Phase 2/Phase 3
Not yet recruiting	`NCT05007795` - Test to Treat TB: Impact of Sputum Sequencing-guided Individualised Therapy on Outcomes in Drug-resistant Tuberculosis	N/A
Completed	`NCT03728725` - Xpert MTB/XDR Clinical Evaluation Trial
Active, not recruiting	`NCT02589782` - Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)	Phase 2/Phase 3
Recruiting	`NCT02619994` - Treatment Shortening of MDR-TB Using Existing and New Drugs	Phase 2
Completed	`NCT01918397` - Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

High-Dose Isoniazid Adjuvant Therapy for Multidrug Resistant Tuberculosis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms